•  Ikaria Acquisition Banner

  • On April 16, 2015, Mallinckrodt Pharmaceuticals acquired Ikaria, Inc., extending Mallinckrodt’s footprint in the hospital market and expanding its reach into neonatal critical care with INOMAX® (nitric oxide for inhalation), a vital treatment option for a highly vulnerable patient population.  It also accelerates Mallinckrodt’s rapid growth in specialty brands - adding significant portfolio diversity with a high-value integrated “drug-device-service” product offering. 

    Individually approved and marketed together as a drug-device combination, INOMAX and proprietary INOMAX delivery systems will benefit from Mallinckrodt’s larger hospital presence, regulatory expertise, long experience in complex drug and device manufacturing, and support of similar medication-technology pairings. 

    Learn more about Mallinckrodt Pharmaceuticals by visiting our company website. >
  • Learn About the Product

     INOmax Logo

    For information on INOMAX and its delivery systems, please visit www.INOMAX.com

    For customer support and contact information, please click here

    Contact Us

    Customer Service:
    Open 24 hours, 7 days a week
    Tel: 1.877.KNOW.INO (1.877.566.9466)

    Perryville III Corporate Park
    53 Frontage Road, Third Floor
    P.O. Box 9001
    Hampton, NJ 08827-9001

    Tel: 908.238.6600
    Fax: 908.238.6633



    INOMAX is a vasodilator, which, in conjunction with ventilatory support and other appropriate agents, is indicated for the treatment of term and near-term (>34 weeks) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension, where it improves oxygenation and reduces the need for extracorporeal membrane oxygenation.

    Utilize additional therapies to maximize oxygen delivery with validated ventilation systems.

    Important Safety Information

    • INOMAX is contraindicated in the treatment of neonates known to be dependent on right-to-left shunting of blood.
    • Abrupt discontinuation of INOMAX may lead to increasing pulmonary artery pressure and worsening oxygenation even in neonates with no apparent response to nitric oxide for inhalation.
    • Methemoglobinemia and NO2 levels are dose dependent. Nitric oxide donor compounds may have an additive effect with INOMAX on the risk of developing methemoglobinemia. Nitrogen dioxide may cause airway inflammation and damage to lung tissues.
    • In patients with pre-existing left ventricular dysfunction, INOMAX may increase pulmonary capillary wedge pressure leading to pulmonary edema.
    • Monitor for PaO2, methemoglobin, and inspired NO2 during INOMAX administration.
    • Use only with an INOMAX DSIR®, INOMAX® DS, or INOVENT® operated by trained personnel.

    Please see full Prescribing Information.


    The INOMAX DSIR and INOMAX DSIR Plus Delivery Systems must only be used in accordance with the indications, usage, contraindications, warnings, and precautions described in the nitric oxide drug package inserts and labeling.